Samsung Biologics announced that it will commence construction of its fifth plant and its second Bio Campus to meet increased market demand. Samsung Biologics will invest KRW 1.9T (~US$1.5B) to build the new facility with a 180,000L manufacturing capacity, bringing its total capacity to 784,000L. It is expected that the site will commence operations in 2025. Plant 4 started partial operations in October 2022 and is expected to commence full operations by mid-2023.
This announcement comes only weeks after Pfizer and Samsung Biologics entered into US$183M biologics CMO agreement.Print Page Mail Article